BC Week In Review | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System brand. The device produces topical platelet-rich plasma (PRP) gel from a patient's own blood and has been approved in...
BC Week In Review | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 2014-06-26   Type: Private placement of senior convertible notes   Raised: $26 million   Shares outstanding prior: 121.7 million   Investor: Deerfield Management  ...
BC Week In Review | May 26, 2014
Clinical News

ALD-401: Phase II data

The double-blind, U.S. Phase II RECOVER-Stroke trial in patients with neurological damage arising from an ischemic stroke showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke missed the primary endpoint of...
BC Week In Review | Apr 7, 2014
Financial News

Cytomedix completes private placement of common stock and warrants

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of common stock and warrants   Raised: $2 million   Shares: 3.8 million   Price: $0.52   Shares after...
BC Week In Review | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc  ...
BC Week In Review | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of senior convertible notes   Raised: $9 million   Placement agent: BTIG   Shares outstanding prior: 114.6 million  ...
BC Week In Review | Dec 16, 2013
Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's AutoloGel System, which isolates and activates platelet-rich plasma (PRP) from a patient's own blood and is then used...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 23, 2013
Company News

Cytomedix dermatology news

Cytomedix will restructure R&D to reduce cash burn and focus on commercializing AutoloGel for chronic wound care. By year end, the company will "substantially" conclude its financial support of the Phase II RECOVER-Stroke trial with...
BC Week In Review | Aug 19, 2013
Company News

Arthrex Inc., Cytomedix deal

Cytomedix granted orthopedic device company Arthrex exclusive, worldwide development and commercialization rights to Cytomedix's Angel Concentrated Platelet Rich Plasma System for five years, with a three year renewal option. Cytomedix received an upfront payment of...
Items per page:
1 - 10 of 60
BC Week In Review | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System brand. The device produces topical platelet-rich plasma (PRP) gel from a patient's own blood and has been approved in...
BC Week In Review | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 2014-06-26   Type: Private placement of senior convertible notes   Raised: $26 million   Shares outstanding prior: 121.7 million   Investor: Deerfield Management  ...
BC Week In Review | May 26, 2014
Clinical News

ALD-401: Phase II data

The double-blind, U.S. Phase II RECOVER-Stroke trial in patients with neurological damage arising from an ischemic stroke showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke missed the primary endpoint of...
BC Week In Review | Apr 7, 2014
Financial News

Cytomedix completes private placement of common stock and warrants

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of common stock and warrants   Raised: $2 million   Shares: 3.8 million   Price: $0.52   Shares after...
BC Week In Review | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc  ...
BC Week In Review | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date completed: 3/31/14   Type: Private placement of senior convertible notes   Raised: $9 million   Placement agent: BTIG   Shares outstanding prior: 114.6 million  ...
BC Week In Review | Dec 16, 2013
Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's AutoloGel System, which isolates and activates platelet-rich plasma (PRP) from a patient's own blood and is then used...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 23, 2013
Company News

Cytomedix dermatology news

Cytomedix will restructure R&D to reduce cash burn and focus on commercializing AutoloGel for chronic wound care. By year end, the company will "substantially" conclude its financial support of the Phase II RECOVER-Stroke trial with...
BC Week In Review | Aug 19, 2013
Company News

Arthrex Inc., Cytomedix deal

Cytomedix granted orthopedic device company Arthrex exclusive, worldwide development and commercialization rights to Cytomedix's Angel Concentrated Platelet Rich Plasma System for five years, with a three year renewal option. Cytomedix received an upfront payment of...
Items per page:
1 - 10 of 60